Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 83 pages | ID: CBB39D8D471EEN
Global Markets Direct

Abstracts

Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Catenin Beta 1 - Drugs In Development, 2022'; Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 23 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

The report 'Catenin Beta 1 - Drugs In Development, 2022' outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Report covers products from therapy areas Oncology, Respiratory, Dermatology, Gastrointestinal, Infectious Disease and Non Malignant Disorders which include indications Colorectal Cancer, Breast Cancer, Liver Cancer, Solid Tumor, Hepatocellular Carcinoma, Melanoma, Unspecified Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Gastric Cancer, Idiopathic Pulmonary Fibrosis, Lung Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Thyroid Cancer, Bladder Cancer, Blood Cancer, Brain Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19), Endometrial Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gastrointestinal Tumor, Head And Neck Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Kidney Cancer (Renal Cell Cancer), Leukemia, Liver Cirrhosis, Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Scar and Small-Cell Lung Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
• The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
3+2 Pharma LLC
Agastiya Biotech LLC
Aileron Therapeutics Inc
Circle Pharma Inc
Dicerna Pharmaceuticals Inc
Entrada Therapeutics Inc
f5 Therapeutics Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
MD2 Biosciences Inc
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Oncology, Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
AB-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
BBI-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Beta catenin Degrader Antibody - Drug Profile
Product Description
Mechanism Of Action
Beta-Catenin Transcriptional Complex Inhibitors - Drug Profile
Product Description
Mechanism Of Action
CBP/beta-Catenin Antagonist - Drug Profile
Product Description
Mechanism Of Action
History of Events
exisulind - Drug Profile
Product Description
Mechanism Of Action
FOG-001 - Drug Profile
Product Description
Mechanism Of Action
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oligonucleotides for Hepatoblastoma - Drug Profile
Product Description
Mechanism Of Action
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRP - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Beta Catenin for Colorectal Cancer and Brain Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CTNNB1 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
ST-316 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Wnt-Driven Diseases - Drug Profile
Product Description
Mechanism Of Action
WNTinib - Drug Profile
Product Description
Mechanism Of Action
WX-024 - Drug Profile
Product Description
Mechanism Of Action
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Featured News & Press Releases
Sep 08, 2022: Propanc Biopharma reports significant effects of PRP against the tumor microenvironment
Aug 23, 2022: Propanc Biopharma synthesizes recombinant trypsinogen & chymotrypsinogen via POP1 joint research & drug discovery program
Jul 28, 2022: Propanc Biopharma’s CSO reflects on unique anti-cancer effects of PRP discovered over past decade
Jul 12, 2022: Propanc Biopharma’s CEO believes lead asset could unlock value as PRP advances to phase I, first-in-human study in advanced cancer patients
Jul 05, 2022: Propanc Biopharma’s CEO comments on the 39 granted patents and 26 patent applications under examination in key global jurisdictions
Jun 22, 2022: Propanc Biopharma’s CSO hails dostarlimab’s impressive results whilst acknowledging more work to be done in the fight against cancer
Jun 01, 2022: Propanc Biopharma believes PRP reduced toxicity will impact cancer patient lives significantly
May 26, 2022: Propanc Biopharma presents 100 years of clinical evidence for “novel” enzyme therapeutic approach to treat cancer
May 18, 2022: Propanc Biopharma undertaking PRP manufacturing & development for human use
May 11, 2022: Propanc Biopharma offers a novel way to stop cancer
May 03, 2022: Agastiya Biotech receives FDA Orphan Drug Designation for AB001 for pancreatic cancer and Acute Myeloid Leukemia (AML)
May 02, 2022: Propanc Biopharma purchases pharma grade raw materials for PRP manufacture in preparation for phase I first-in-human study
Apr 13, 2022: Propanc Biopharma’s management explains why they believe cancer patients are likely to respond to PRP treatment
Apr 11, 2022: Sapience Therapeutics presents late-breaking data on ST316 at AACR 2022
Mar 22, 2022: Propanc Biopharma receives notice of allowance for method to treat cancer stem cells from the US Patent & Trademark Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022